TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03612973

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: lipid profile
Description: Serum samples will be withdrawn after fasting 12 hours then performed on Siemens Dimension Max: Total cholesterol and triglyceride concentrations will be estimated using enzymatic methods ( Roche Diagnostics, Mannheim, Germany). High density lipoprotein cholesterol will be determined after precipitation with phosphotungstic acid/magnesium chloride. Low density lipoprotein(LDL) cholesterol will be measured directly with a commercially available direct LDL-C assay (LDL-C Plus assay; Roche Diagnostics)

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: lipid profile
Description: Serum samples will be withdrawn after fasting 12 hours then performed on Siemens Dimension Max: Total cholesterol and triglyceride concentrations will be estimated using enzymatic methods ( Roche Diagnostics, Mannheim, Germany). High density lipoprotein cholesterol will be determined after precipitation with phosphotungstic acid/magnesium chloride. Low density lipoprotein(LDL) cholesterol will be measured directly with a commercially available direct LDL-C assay (LDL-C Plus assay; Roche Diagnostics)

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: fasting insulin
Description: serum samples used for doing the test by ELISA after fasting for 8 h

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: fasting insulin
Description: serum samples used for doing the test by ELISA after fasting for 8 h

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: fibro scan
Description: liver stiffness by fibro scan before and after treatment

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: fibro scan
Description: liver stiffness by fibro scan before and after treatment
Study: NCT03215888

Intervention type: PROCEDURE
Intervention: bariatric surgery
Description: Obese patients will undergo brain imaging, neurocognitive function testing and measurement of insulin resistance and inflammatory markers pre- and post bariatric surgery
Study: NCT04661553

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mueller's polarimetric colposcopy Group 2
Description: Determination of the best polarimetric biomarkers reflecting the status of the cervical microstructure throughout its remodeling process due to the pregnancy in a population at high-risk of preterm birth.~This polarimetric biomarkers should make it possible to accurately determine the time remaining before childbirth for an abnormal pregnancy and, therefore, to predict premature childbirth.
Study: NCT01384643

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propofol
Description: Induction of anesthesia: Propofol 1 mg/kg, sufentanil 1.0-3.0 µg/kg and rocuronium 50 mg IV Maintenance of anesthesia (pre CPB): Propofol 120-600 µg ∙ kg-1 ∙ h-1 , sufentanil 0.15-0.3 µg ∙ kg-1 ∙ h-1, vecuronium 8-10 mg/h IV infusion Maintenance of anesthesia (during CPB): Propofol 120-600 µg ∙ kg-1 ∙ h-1 IV infusion Weaning from CPB: Sufentanil 50 µg IV Maintenance of anesthesia (post CPB): Propofol 120-600 µg ∙ kg-1 ∙ h-1 , sufentanil 0.15-0.3 µg ∙ kg-1 ∙ h-1, vecuronium 8-10 mg/h IV infusion Propofol infusion rate is titrated using bispectral index (40-60).
Study: NCT02971696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Sorafenib will be administrated at a dose of 400 mg twice daily (consisting of two 200-mg tablets).Treatment interruptions and up to two dose reductions (first to 400 mg once daily and then to 400 mg every 2 days) will permitted for drug- related adverse effects. If further dose reductions will required, patients will withdraw from the study
Study: NCT04253171

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lithoplasty
Description: The lithoplasty balloon should be utilized as early as possible. If it is necessary for passage of the lithoplasty balloon, the lesion may first be predilated with an undersized conventional balloon, non-compliant or semi-compliant. If passage of the lithoplasty balloon is still not possible, it is recommended to perform rotational atherectomy with a small burr size.~The lithoplasty balloon is sized 1:1 to reference diameter. Lithoplasty is performed with the balloon dilated at 4 atmospheres, and 10 shocks are delivered, after which the balloon is expanded to 6 atmospheres for 30 seconds, and then deflated. Up to 8 series of balloon expansion/deflation can be delivered in this manner if necessary, and several balloons may be used for long lesions.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional
Description: Lesion preparation is performed starting with conventional balloons, non-compliant or semi-compliant. Unless fully satisfactory dilatation is achieved with conventional balloons, it is recommended to also use modified balloons (scoring balloons, cutting balloons). If balloons cannot be passed or if dilatation is inadequate, the lesion may first be predilated with an undersized conventional, non-compliant, or semi-compliant balloon. If necessary, rotational atherectomy with a small burr size can be used to facilitate adequate balloon preparation.
Study: NCT01276496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilengitide
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT03336788

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Transcranial Magnetic Stimulation (TMS - ) MagPro®
Description: 20 sessions navigated with Conventional Transcranial Magnetic Stimulation
Study: NCT02971696

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Best Supportive care
Description: Liver Support, pain management
Study: NCT02625142

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Family-centered rounds checklist tool
Description: A printed checklist containing 9 key tasks associated with effective delivery of family-centered rounds. A previously-identified member of each rounding team was responsible for holding the printed checklist during morning rounds. Team members were trained the in the use of this checklist prior to the post-intervention period, and a brief refresher training was conducted mid-way through the period.
Study: NCT03907631

Intervention type: OTHER
Intervention: Standard of care
Description: care decisions driven by local physicians; this is an observational cohort
Study: NCT01384643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Induction of anesthesia: Propofol 1 mg/kg, sufentanil 1.0-3.0 µg/kg and rocuronium 50 mg IV Maintenance of anesthesia (pre CPB): Propofol 120-600 µg ∙ kg-1 ∙ h-1 , sufentanil 0.15-0.3 µg ∙ kg-1 ∙ h-1, vecuronium 8-10 mg/h IV infusion Maintenance of anesthesia (during CPB): Propofol 120-600 µg ∙ kg-1 ∙ h-1 IV infusion Weaning from CPB: Sufentanil 50 µg IV Maintenance of anesthesia (post CPB): Propofol 120-600 µg ∙ kg-1 ∙ h-1 , sufentanil 0.15-0.3 µg ∙ kg-1 ∙ h-1, vecuronium 8-10 mg/h IV infusion Propofol infusion rate is titrated using bispectral index (40-60).
Study: NCT02351986

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: physical therapy
Description: A 20 minutes ice pack cryotherapy applied for 4 consecutive days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ice pack
Study: NCT03961373

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gastrectomy with D2 lymphadenectomy
Description: Patients who are assigned to the neoadjuvant chemotherapy+ surgical D2 treatment group will undergo either subtotal or total gastrectomy, depending on the location of the primary tumour. Standardized D2-lymph node dissection is required with specific information about lymph node stations.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gastrectomy with D2plus lymphadenectomy
Description: Patients who are assigned to the neoadjuvant chemotherapy + surgical D2+ extended lymphadenectomy treatment group will undergo either subtotal or total gastrectomy, depending on the location of the primary tumour. Standardized D2+ lymph node dissection plus resection of stations 8p, 12p, 13, 14v, 16a2/b1 is required with specific information about lymph node stations.
Study: NCT01095471

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PCV13
Description: Immunisation with the 13-valent pneumococcal conjugate vaccine (PCV13) at approximately 40 months of age.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PCV13
Description: Immunisation with the 13-valent pneumococcal conjugate vaccine (PCV13) at approximately 40 months of age.
Study: NCT02992080

Intervention type: OTHER
Group type: OTHER
Intervention: miRNAs isolation from blood samples of patients and control
Description: Blood sample collection in specific PAXGene tubes

Intervention type: OTHER
Group type: OTHER
Intervention: miRNAs isolation from blood samples of patients and control
Description: Blood sample collection in specific PAXGene tubes

Intervention type: OTHER
Group type: OTHER
Intervention: miRNAs isolation from blood samples of patients and control
Description: Blood sample collection in specific PAXGene tubes
Study: NCT04608942

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Jett Plasma Medical Lift
Description: Plasma Application versus Mechanical Debridement in refractory meibomian gland dysfunction

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical Debridement
Description: Plasma Application versus Mechanical Debridement in refractory meibomian gland dysfunction
Study: NCT00566501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: Donepezil SR 23 mg once daily orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: Donepezil SR 23 mg once daily orally.
Study: NCT02660398

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standardized NMBD Management
Description: The intervention phase will introduce a standardized research protocol that spells out NMBD management, including how muscle relaxant should be administered and monitored, and how reversal with neostigmine should be done.
Study: NCT01227148

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tightly glucose control
Description: A continuous insulin infusion (50 IU of Actrapid HM) in 49.5 ml of 0.9 percent sodium chloride with the use of a pump was started when blood glucose level exceeded 140 mg/dl to maintain a blood glucose level of between 120 and 140 mg per deciliter. The dose of insulin was adjusted according to whole-blood glucose levels, measured at one-four-hour interval in arterial blood or arterial catheter was not available. The insulin dose was adjusted by a neuro-fuzzy method

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional glucose control
Description: a continuous insulin infusion was delivered when the blood glucose level exceeded 200 mg/dl and insulin level was then adjusted to maintain a blood glucose level of between 180 and 200 mg per deciliter.
Study: NCT04079569

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tobacco
Description: Quit Smoking For a Healthy Family - This is a family-based psycho-education intervention using lay health worker (LHW) outreach. LHW will be trained to recruit smoke-family dyads and provide education and information about tobacco and health, and smoking cessation resources through 2 small-group education sessions and 2 individual phone calls over a 2-month period.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Living
Description: In this comparison arm, participants will receive the same number of contacts on the same schedule and in the same format (2 small group sessions and 2 telephone calls). The comparison LHWs will receive training about Healthy Living focusing on nutrition and physical activity education. Participants will also receive the Smoking Cessation Resource Handout.
Study: NCT01642654

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The WG was submitted to a 16-week WEP, with combined aerobic and resistance exercises in three weekly sessions. Water temperature was approximately 30º C with an average ambient temperature of 34° C. The pool had water levels ranging between 1,20 and 1,40 meters deep.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational lectures
Description: Educational lectures
Study: NCT01269788

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoxetine
Description: 20 mg , oral , daily 30 mins before breakfast, for 6 weeks
Study: NCT03336788

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation (TMS - ) MagPro®
Description: 20 sessions navigated with Conventional Transcranial Magnetic Stimulation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: virtual reality for displaying interactive virtual environments
Description: 20 sessions navigated with virtual reality
Study: NCT04349696

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitiglinide
Description: Day 1: one tablet of Mitiglinide 10mg with 240 ml of water approximately 5 mins before breakfast. An indwelling non-heparin catheter will be placed in an antecubital vein of the forearm or direct venipuncture will be adopted for blood sample collection at belowing time point:~For PK evaluation:~-30 (Predose), 5, 10, 15, 20, 30 min, 1.0, 1.5, 2.0, 3.0, 4.0, 5.0, 6.0, 7.0, 8.0, 9.0, 10 hr post dose (a total of 17 samples per subject)~For PD evaluation:~-30 (Predose), 15, 30 min, 1.0, 1.5, 2.0, 3.0, 4.0 hours post dose (a total of 8 samples per subject)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitiglinide
Description: Day 1: one tablet of Mitiglinide 10mg with 240 ml of water approximately 5 mins before breakfast. An indwelling non-heparin catheter will be placed in an antecubital vein of the forearm or direct venipuncture will be adopted for blood sample collection at belowing time point:~For PK evaluation:~-30 (Predose), 5, 10, 15, 20, 30 min, 1.0, 1.5, 2.0, 3.0, 4.0, 5.0, 6.0, 7.0, 8.0, 9.0, 10 hr post dose (a total of 17 samples per subject)~For PD evaluation:~-30 (Predose), 15, 30 min, 1.0, 1.5, 2.0, 3.0, 4.0 hours post dose (a total of 8 samples per subject)
Study: NCT01632306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2090314
Description: LY2090314 administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2090314
Description: LY2090314 administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2090314
Description: LY2090314 administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX
Description: FOLFOX administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine administered IV
Study: NCT04908527

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking to OR
Description: Patients, after being prepared for the OR, walk to the operating room
Study: NCT02605538

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vaccination with vaccine against hepatitis A and B
Description: Vaccination against hepatitis A and B

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vaccination with vaccine against hepatitis A and B
Description: Vaccination against hepatitis A and B
Study: NCT04558138

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Discharge timing
Description: Patients will be discharged home on the day of surgery as opposed to POD #1
Study: NCT01063803

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATN-103
Description: A single subcutaneous injection of ATN-103 every 4 weeks (approx 13 SC injections during the study)
Study: NCT01269788

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole
Description: 20 mg , oral , daily 30 mins before breakfast, for 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral , daily 30 mins before breakfast, for 6 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole
Description: 20 mg , oral , daily 30 mins before breakfast, for 6 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoxetine
Description: 20 mg , oral , daily 30 mins before breakfast, for 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral , daily 30 mins before breakfast, for 6 weeks
Study: NCT03906188

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LitEmotion
Description: LitEmotion is a serious video game programmed for helping managing emotions. The experimental group will play during 3 weeks while the control group will not play. The sample will play during 21 days, one session daily, around 45 minutes. After the 21 sessions the group will stop playing during 3 weeks. Therefore, the scales are done three times. In the very beginning (before playing), 21 days after playing, and, finally, 21 days no playing.
Study: NCT01393015

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automated settings on the oxygen delivery device
Description: FreeO2 automatically adjusts the oxygen flow delivered to patients based on the SpO2 signal. Patients keep using the same device for duration of hospitalization.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Manual settings with FreeO2 system in collection mode
Description: Oxygen flow delivery is adjust by nurse and respiratory therapists. Standard medical treatment. Patients keep using the same device for duration of hospitalization.
Study: NCT00910468

Intervention type: PROCEDURE
Intervention: Robot-assisted Laparoscopic myomectomy
Description: Robot-assisted Laparoscopic myomectomy
Study: NCT00877474

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PM01183
Description: Vials containing 0.2 mg of PM01183 as powder for concentrate for solution for infusion
Study: NCT01125501

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Protandim
Description: The product Protandim used in this study have ingredients derived from five botanical sources \[Bacopa monniera, Silybum marianum (milk thistle), Withania somnifera (Ashwagandha), Camellia sinensis (green tea), and Curcuma longa (turmeric)\].

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Protandim
Description: The product Protandim used in this study have ingredients derived from five botanical sources \[Bacopa monniera, Silybum marianum (milk thistle), Withania somnifera (Ashwagandha), Camellia sinensis (green tea), and Curcuma longa (turmeric)\].
Study: NCT02051816

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Video Laryngoscopy
Study: NCT04349761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MyMD1
Description: Isomyosamine 5mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT01924143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-9855
Description: radiolabeled (100 µCi \[14C\]-Labeled) TD-9855 (20 mg)
Study: NCT00803140

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cautery vs Active Control Arm (Scalpel)
Description: Interventions: The cautery used will be the standard operating room monopolar cautery used at our institution. The cautery will be used on a cut setting of 20 with a blend setting of zero (pure cut). A standard protected needle tip cautery will be used.~A #15 blade carbon steel scalpel blade will be used on ½ of the incision; a cautery device with the above-mentioned settings will be used on the other ½ of the wound. The patient will be randomly assigned to receive the cautery incision on the left or right side. The same surgeon will make all of the skin incisions and perform the skin closures in order to provide as much standardization as possible.~The closure will be standardized.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cautery vs Active Control Arm (Scalpel)
Description: Interventions: The cautery used will be the standard operating room monopolar cautery used at our institution. The cautery will be used on a cut setting of 20 with a blend setting of zero (pure cut). A standard protected needle tip cautery will be used.~A #15 blade carbon steel scalpel blade will be used on ½ of the incision; a cautery device with the above-mentioned settings will be used on the other ½ of the wound. The patient will be randomly assigned to receive the cautery incision on the left or right side. The same surgeon will make all of the skin incisions and perform the skin closures in order to provide as much standardization as possible.~The closure will be standardized.
Study: NCT00305890

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Behavioral Weight Management Program
Description: The lifestyle behavioral weight management program will focus on lifestyle, exercise, attitudes, relationships, and nutrition. Participants will attend 12 weekly group sessions, followed by 6 every-other-week group sessions.
Study: NCT02345369

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Locked Set Screw
Description: Fixation of hip fracture with intramedullary hip screw with locking of the set screw

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Unlocked Set Screw
Description: Fixation of hip fracture with intramedullary hip screw without locking of the set screw
Study: NCT02292381

Intervention type: OTHER
Intervention: Isometric exercise

Intervention type: OTHER
Intervention: Isometric exercise
Study: NCT01632306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Nab-paclitaxel administered IV
Study: NCT00615667

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus (FK506)
Description: Started: 0.05-0.1mg/kg/d,divided into two daily dose at 12hr; the blood level:5-10ng/ml in induction phase;and 4-6ng/ml in maintenance phase;
Study: NCT00448825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate + Cognitive Behavioral Therapy
Description: Topiramate up to 300 mg per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + Cognitive Behavioral Therapy
Description: Placebo twice a day